ClinicalTrials.gg
CompletedNCT01188928Updated Mar 10, 2025Results posted

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

A Phase 3 interventional study of Calcipotriol plus betamethasone and Betamethasone-17,21-dipropionate in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
4th of 47
1,152 · median 200
Started
2010
the only one that year
Phase 3
17 of 47
none open now
Registered
18th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 17 in phase 3, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained prior to any trial related activities (including any ).
  • Aged 18 years or above
  • Either sex
  • Any race or ethnicity
  • Attending a hospital outpatient clinic or the private practice of a board certified dermatologist.
  • Clinical diagnosis of stable plaque psoriasis vulgaris of at least 6 months duration involving the non-scalp regions of the body (trunk and/or limbs) amenable to treatment with a maximum of 100 g of topical medication per week.
  • An investigator's global assessment of disease severity (IGA) of mild or moderate on the body (trunk and/or limbs) at Day 0 (Visit 1).
  • A minimum modified Psoriasis Area and Severity Index (PASI) score for extent of 2 in at least one body region (i.e. psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)
  • Females of must have a negative pregnancy test at Day 0 (Visit 1).
  • Females of childbearing potential must agree to use a highly effective method of during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year) such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomised partner. The patients must have used the contraceptive method continually for at least 1 month prior to the pregnancy test, and must continue using the contraceptive method for at least 1 week after the last application of study medication. A female is defined as not of child-bearing potential if she is (12 months with no menses without an alternative medical cause), or surgically sterile (tubal ligation/section, hysterectomy or bilateral ovariectomy).
  • Able to communicate with the investigator and understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:

    • etanercept - within 4 weeks prior to randomisation
    • adalimumab, alefacept, infliximab - within 2 months prior to randomisation
    • ustekinumab - within 4 months prior to randomisation
    • experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to randomisation
  • Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., , retinoids, methotrexate, cyclosporine and other ) within 4 weeks prior to randomisation.
  • PUVA or Grenz ray therapy within 4 weeks prior to randomisation.
  • UVB therapy within 2 weeks prior to randomisation.
  • Any topical treatment of the trunk and/or limbs (except for emollients) within 2 weeks prior to randomisation.
  • Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with class 1- 5 corticosteroids or vitamin D analogues within 2 weeks prior to randomisation.
  • Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with class 1-5 corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation.
  • Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, anti-malarials, lithium, ACE inhibitors) during the study.
  • Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Subjects with any of the following conditions present on the treatment area: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, icthyosis, acne rosacea, ulcers and wounds.
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia.
  • Known or suspected severe renal insufficiency or severe hepatic disorders.
  • Known or suspected to component(s) of the products.
  • Current participation in any other interventional clinical study.
  • Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation or longer, if the class of substance required a longer washout as defined above (e.g. biological treatments).
  • Planned excessive exposure to the sun during the study that may affect the psoriasis vulgaris.
  • Previously randomised in this study.
  • Females who are pregnant, have a positive pregnancy test at Day 0 (Visit 1), or are breast-feeding. Females of wishing to become pregnant during the study, or not using an adequate method of during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,152 participants (actual)

Study arms

  • Experimental
    LEO 80185

    Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension

    Drug: Calcipotriol plus betamethasone

  • Active comparator
    Betamethasone

    Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle

    Drug: Betamethasone-17,21-dipropionate

  • Active comparator
    Calcipotriol

    Calcipotriol 50 mcg/g in the topical suspension vehicle

    Drug: Calcipotriene

  • Placebo comparator
    Topical suspension vehicle

    The topical suspension vehicle alone

    Drug: Topical suspension vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4

    The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.

    Time frame: 4 weeks

  2. Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8

    The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.

    Time frame: week 8

Secondary outcomes

  1. Mean Percentage Change in PASI From Baseline to Week 4

    At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.

    Time frame: Baseline and 4 weeks

  2. Mean Percentage Change in PASI From Baseline to Week 8

    At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.

    Time frame: Baseline and 8 weeks

07

Results

Posted Apr 9, 2013

Participant flow

The first subject's first visit was on 27-SEP-2010 and the last subject's last visit was on 29-MAR-2011. Hence the study had a duration of 26 weeks.

Participant flow — Overall Study
MilestoneLEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Started4824799695
Completed4444178277
Not completed38621418

Outcome measures

PrimaryControlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4

The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.

Time frame:
4 weeks
Reported as:
Number · participants
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4
participantsLEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4646052
PrimaryControlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8

The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.

Time frame:
week 8
Reported as:
Number · participants
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8
participantsLEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8140103146
SecondaryMean Percentage Change in PASI From Baseline to Week 4

At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · percentage of change in PASI
Mean Percentage Change in PASI From Baseline to Week 4
percentage of change in PASILEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Mean Percentage Change in PASI From Baseline to Week 4-46.4 ± 30.2-42.7 ± 29.4-32.2 ± 27.3-17.4 ± 36.8
SecondaryMean Percentage Change in PASI From Baseline to Week 8

At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.

Time frame:
Baseline and 8 weeks
Reported as:
Mean · percentage of change in PASI
Mean Percentage Change in PASI From Baseline to Week 8
percentage of change in PASILEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Mean Percentage Change in PASI From Baseline to Week 8-55.8 ± 34.4-48.6 ± 35.8-43.6 ± 34.1-20.9 ± 49.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 80185—1/482 (0.2%)14/482 (2.9%)
Betamethasone—7/479 (1.5%)15/479 (3.1%)
Calcipotriol—0/96 (0%)5/96 (5.2%)
Topical Suspension Vehicle—1/95 (1.1%)3/95 (3.2%)
Most frequent serious events
Most frequent serious events
EventLEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
Suicide attemptPsychiatric disorders0/4820/4790/961/95
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/4821/4790/960/95
Alcohol poisoningInjury, poisoning and procedural complications0/4821/4790/960/95
CellulitisInfections and infestations0/4821/4790/960/95
Cholecystitis acuteHepatobiliary disorders0/4821/4790/960/95
HaematuriaRenal and urinary disorders0/4821/4790/960/95
NephrolithiasisRenal and urinary disorders0/4821/4790/960/95
Stent placementSurgical and medical procedures0/4821/4790/960/95
Suicidal ideationPsychiatric disorders0/4821/4790/960/95
HypertensionVascular disorders1/4820/4790/960/95
Most frequent other events
Most frequent other events
EventLEO 80185BetamethasoneCalcipotriolTopical Suspension Vehicle
NasopharyngitisInfections and infestations14/48215/4795/963/95

Baseline characteristics

Age, Continuous
Age, Continuous(years)LEO 80185BetamethasoneCalcipotriolTopical Suspension VehicleTotal
Mean48.7 ± 13.448.5 ± 13.848 ± 13.749.4 ± 13.048.6 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)LEO 80185BetamethasoneCalcipotriolTopical Suspension VehicleTotal
Female1981933635462
Male2842866060690
Region of Enrollment
Region of Enrollment(participants)LEO 80185BetamethasoneCalcipotriolTopical Suspension VehicleTotal
United States48247996951152
08

Study locations

59 sites
  • Horizon Research Group, Inc
    Mobile, Alabama 36606, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • DBA Torrance Clinical Research
    Lomita, California 90717, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • Skin Surgery Medical Group, Inc.
    San Diego, California 92117, United States
  • Walter Nahm, MD, Ph.D., Inc
    San Diego, California 92123, United States
  • Coastal Medical Research Group, Inc.
    San Luis Obispo, California 93401, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Dermatology Research Centers
    Santa Monica, California 90404, United States
  • Colorado Medical Research Center, Inc.
    Denver, Colorado 80120, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33472, United States
  • Dermatology Associates and Research
    Coral Gables, Florida 33134, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Atlanta Dermatology, Vein & Research Center
    Alpharetta, Georgia 30022, United States
  • Peachtree Dermatology Associates
    Atlanta, Georgia 30327, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • Gwinnett Clinical Research Center, Inc
    Snellville, Georgia 30078, United States
  • Altman Dermatology Associates
    Arlington Hts, Illinois 60005, United States
  • Glazer Dermatology
    Buffalo Grove, Illinois 60089, United States
  • Deaconess Clinic, Inc.
    Evansville, Indiana 47713, United States
  • Hudson Dermatology
    Evansville, Indiana 47714, United States
  • Dawes Fretzin Clinical Research Group
    Indianapolis, Indiana 46256, United States
  • Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Dermatology Specialists
    Louisville, Kentucky 40202, United States
  • Owensboro Dermatology Associates
    Owensboro, Kentucky 42303, United States
  • Lawrence J. Green, MD, LLC
    Rockville, Maryland 20850, United States
  • David Fivenson, MD Dermatology, PLC
    Ann Arbor, Michigan 48103, United States
  • Great Lakes Research Group, Inc
    Bay City, Michigan 48706, United States
  • Michigan Center for Research Corp.,
    Clinton Township, Michigan 48038, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Karl G. Heine, M. D. Dermatology
    Henderson, Nevada 89052, United States
  • Psoriasis Treatment Center of Central NJ
    East Windsor, New Jersey 08520, United States
  • Anderson & Collins Clinical Research, Inc.
    Edison, New Jersey 08817, United States
  • The Dermatology Group, PC
    Verona, New Jersey 07044, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Derm Research Center of New York
    Stony Brook, New York 11790, United States
  • Triangle Medical Research Associates, LLC
    Cary, North Carolina 27518, United States
  • Haber Dermatology and Cosmetic Surgery
    South Euclid, Ohio 44118, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • King-Maceyko Dermatology Associates
    Johnstown, Pennsylvania 15905, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • J&S Studies, Inc.
    College Station, Texas 77845, United States
  • Division of Dermatology, Baylor Research Institute
    Dallas, Texas 75246, United States
  • Centre for Clinical Studies
    Houston, Texas 77030, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Progressive Clinical Research, P.A.
    San Antonio, Texas 78229, United States
  • Dermatology Research Center, Inc.
    Salt Lake City, Utah 84117, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 2 years 1 month after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2010
First posted
Aug 26, 2010
Start
Sep 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results delay requested
Jan 11, 2013
Results first posted
Apr 9, 2013
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01188928
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Aug 26, 2010
Start date
Sep 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Apr 9, 2013
Last update
Mar 10, 2025

Study contacts

Alan Menter, MD
principal investigator · Division of Dermatology, Baylor Research Institute, USA
Stephen Tyring, MD PhD
principal investigator · Center for Clinical Studies
Steven A Davis, MD
principal investigator · Dermatology Clinical Research Center of San Antonio
David J Cohen, MD
principal investigator · Dermatologic Surgery Specialists
Mark Lee, MD
principal investigator · Progressive Clinical Research
Tiffani K Hamilton, MD
principal investigator · Atlanta Dermatology, Vein & Research Center
Daniel M Stewart, DO
principal investigator · Michigan Center for Research Corp.
John J Goodman, MD
principal investigator · Palm Beach Research Center
Terry Jones, MD
principal investigator · J&S Studies, Inc
Dow Stough, MD
principal investigator · Burke Pharmaceutical Research
Jerry Bagel, MD
principal investigator · Psoriasis Treatment Center of Central NJ
James A Solomon, MD PhD
principal investigator · Ameriderm Research
George J Murakawa, MD PhD
principal investigator · Somerset Skin Centre
Michael Bukhalo, MD
principal investigator · Altman Dermatology Associates
Jeffrey Moore, MD
principal investigator · Deaconess Clinic, Inc.
Jaime D Weisman, MD
principal investigator · Peachtree Dermatology Associates Research Center
Jonathan Kantor, MD
principal investigator · North Florida Dermatology Associates
David Rodriguez, MD
principal investigator · Dermatology Associates and Research
Leonard Swinyer, MD
principal investigator · Dermatology Research Center, Inc
Alicia Bucko, MD
principal investigator · Academic Dermatology Associates
Johnathan Weiss, MD
principal investigator · Gwinnett Clinical Research Center, Inc
William P Werschler, MD
principal investigator · Premier Clinical Research
Mark Lebwohl, MD
principal investigator · Icahn School of Medicine at Mount Sinai
James Swinehart, MD
principal investigator · Colorado Medical Research Center, Inc.
Steve Kempers, MD
principal investigator · Minnesota Clinical Study Center
Dale Martin, MD
principal investigator · Skin Surgery Medical Group, Inc.
Scott Guenthner, MD
principal investigator · Indiana Clinical Trials Center
Kenneth Dawes, MD
principal investigator · Dawes Fretzin Clinical Research Group
Scott Glazer, MD
principal investigator · Glazer Dermatology
Karl G Heine, MD
principal investigator · Karl G. Heine, M. D. Dermatology
Fasahat Hamzavi, MD
principal investigator · Hamzavi Dermatology
Joseph Samady, MD
principal investigator · Dermatology Specialists, Inc.
Artis P Truett III, MD
principal investigator · Owensboro Dermatology Associates
Phoebe Rich, MD
principal investigator · Oregon Dermatology and Research Center
Robin Shecter, DO
principal investigator · VISIONS CLINICAL RESEARCH
Robert Haber, MD
principal investigator · Haber Dermatology and Cosmetic Surgery
David Kerr, MD
principal investigator · Horizons Clinical Research Center, LLC
David Fivenson, MD
principal investigator · David Fivenson, MD Dermatology, PLC
Walter Nahm, MD PhD
principal investigator · Walter Nahm, MD, Ph.D., Inc
Steven Grekin, DO
principal investigator · Grekin Skin Institute
Joseph F Fowler, MD
principal investigator · Dermatology Specialists
Jose E Mendez, DO
principal investigator · International Dermatology Research, Inc.
David M Stoll, MD
principal investigator · Dermatology Research Centers
Paul S Yamauchi, MD
principal investigator · Clinical Science Institute
Robert Nossa, MD
principal investigator · The Dermatology Group, PC
Chernila Selbert Alan, MD
principal investigator · DBA Torrance Clinical Research
Brent M Boyce, MD
principal investigator · Great Lakes Research Group, Inc
David B Friedman, MD
principal investigator · Advanced Clinical Research Institute
Andrew King, MD
principal investigator · King-Maceyko Dermatology Associates
Catherine Hren, MD
principal investigator · Triangle Medical Research Associates, LLC
Elyse S Rafal, MD
principal investigator · Derm Research Center of New York
John Siebenlist, MD
principal investigator · West Dermatolgy
Linda Stein Gold, MD
principal investigator · Henry Ford Health System
Laura K Ferris, MD PhD
principal investigator · University of Pittsburgh Medical Center
Elizabeth Hughes Tichy, MD
principal investigator · Clinical Trials of Texas, Inc.
Jane M Lee, MD
principal investigator · Anderson & Collins Clinical Research, Inc.
Charles P Hudson, MD
principal investigator · Hudson Dermatology
Amy M Morris, MD
principal investigator · Horizon Research Group, Inc.
Lawrence Green, MD
principal investigator · Lawrence J. Green, MD, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone

Start the discussion